NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, Forecast & News

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) announced its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.03. View Brainstorm Cell Therapeutics' Earnings History.

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Brainstorm Cell Therapeutics.

1 analysts have issued 1 year price targets for Brainstorm Cell Therapeutics' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Brainstorm Cell Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 106.9% from the stock's current price. View Analyst Price Targets for Brainstorm Cell Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Brainstorm Cell Therapeutics.

Media headlines about BCLI stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Brainstorm Cell Therapeutics earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Brainstorm Cell Therapeutics.

Some companies that are related to Brainstorm Cell Therapeutics include Cabaletta Bio (CABA), PDL BioPharma (PDLI), Harpoon Therapeutics (HARP), Eiger Biopharmaceuticals (EIGR), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Scholar Rock (SRRK), Compugen (CGEN), CASI Pharmaceuticals (CASI), Sutro Biopharma (STRO), ADMA Biologics (ADMA), Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), Novavax (NVAX) and Solid Biosciences (SLDB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix Biotherapeutics (PLX), Sangamo Therapeutics (SGMO), IsoRay (ISR), Mellanox Technologies (MLNX), Ionis Pharmaceuticals (IONS), Caladrius Biosciences (CLBS) and Abeona Therapeutics (ABEO).

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BCLI stock can currently be purchased for approximately $4.35.

Brainstorm Cell Therapeutics has a market capitalization of $98.35 million. The biotechnology company earns $-13,950,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.View Additional Information About Brainstorm Cell Therapeutics.

The official website for Brainstorm Cell Therapeutics is http://www.brainstorm-cell.com/.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]